Fortnightly review: drug treatment of epilepsy.
Feely
M
M
Clinical Pharmacology Unit, Division of Medicine, University of Leeds, General Infirmary, Leeds LS1 3EX. mfeely@ulth.northy.nhs.uk
D000085:Acetates / Q000627:therapeutic use; D000588:Amines; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D001463:Barbiturates / Q000627:therapeutic use; D001569:Benzodiazepines; D000078306:Clobazam; D002998:Clonazepam / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids; D004049:Diethylcarbamazine / Q000627:therapeutic use; D004827:Epilepsy / Q000188:drug therapy*; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D000077236:Topiramate; D014635:Valproic Acid / Q000627:therapeutic use; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D000085:Acetates; D000588:Amines; D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D001463:Barbiturates; D003509:Cyclohexanecarboxylic Acids; D000077236:Topiramate; D001569:Benzodiazepines; D000078306:Clobazam; D005632:Fructose; D005680:gamma-Aminobutyric Acid; D002998:Clonazepam; D014635:Valproic Acid; D000077206:Gabapentin; D020888:Vigabatrin; D004049:Diethylcarbamazine